<DOC>
	<DOCNO>NCT00839826</DOCNO>
	<brief_summary>Patients undergo surgery , especially hip knee surgery , high risk VTE ( 60 % without prophylaxis ) . The administration drug thromboprophylaxis , heparin , significantly lower risk , heparin apply skin ( subcutaneously ) . Additionally , chance develop heparin-induced thrombocytopenia ( decrease platelet ) . Therefore , still need new agent safer efficient easy apply.The purpose study compare safety efficacy BAY 59-7939 safety efficacy license drug Enoxaparin . Enoxaparin , so-called low molecular heparin , approve widely use area thromboprophylaxis give daily subcutaneously.Another important purpose study find optimal dose BAY 59-7939 thromboprophylaxis hip replacement surgery . Therefore , several dose step plan .</brief_summary>
	<brief_title>ODiXahip - Phase IIa Dose Escalating Proof Principle Trial</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male patient age 18 year postmenopausal female patient . Patients schedule elective primary total hip replacement ( cement noncemented prosthesis ) . Patients ' write informed consent participation receive detailed write oral previous information study specific procedure . DVT PE within previous 6 month prior study entry . Myocardial infarction ( MI ) cerebrovascular attack ( CVA ) , TIA ischaemic stroke within last 6 month prior study entry . History heparininduced thrombocytopenia , allergy heparin . Intracerebral intraocular bleeding within last 6 month prior study entry . History gastrointestinal disease gastrointestinal bleeding within last 6 month prior study . History presence gastrointestinal disease could result impaired absorption study drug Amputation one leg.Related current symptom finding Heart insufficiency NYHA IIIIV . Congenital acquire haemorrhagic diathesis ( PT INR/aPTT within normal limit ) . Thrombocytopenia ( platelet &lt; 50.000/Âµl ) . Macroscopic haematuria . Allergy contrast medium . Severe hypertension ( SBP &gt; 200mmHg , DBP &gt; 100 mmHg ) . Impaired liver function ( transaminases &gt; 2 x ULN ) . Impaired renal function ( serum creatinine &gt; 1.5 x ULN ) . Active malignant disease . Presence active peptic ulcer gastrointestinal disease increase risk gastrointestinal bleeding . Body weight &lt; 45 kg . Drug alcohol abuse . Related current treatment Therapy oral anticoagulant ( e.g . phenprocoumon , warfarinsodium ) . Therapy acetylic salicylic acid thrombocyte aggregation inhibitor ( e.g . clopidogrel , dipyridamole ticlopidine ) stop one week enrolment Treatment heparins Factor Xa Inhibitors study medication . All drug influence coagulation , ( exception : NSAIDs half life &lt; 17 hr allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention Thromboembolism total hip replacement</keyword>
</DOC>